The University of Arizona Health Sciences eNewsletter
January 2019

Roberta Diaz Brinton, PhD, inaugural director of the Center for Innovation in Brain Science at the UA Health Sciences, received $5.9 million from the National Institute on Aging to study the role of gender in Alzheimer’s disease and develop precision medicine interventions to prevent — and potentially reverse — the course of the disease in both women and men.

An increasing proportion of all cardiac arrests occurring outside of the hospital are related to drug overdoses, according to a new study conducted by two UA College of Medicine – Phoenix students.
Using a $2.1 million grant from the National Institute of Neurological Disorders and Stroke, a team of UA researchers from the Colleges of Engineering, Public Health and Pharmacy are creating faster MRI technologies to accommodate challenging patient populations, including stroke patients, individuals with Parkinson's disease and children.
Thanks to a recent gift from the Banner Health Foundation the UA Department of Family and Community Medicine’s Mobile Health Program will be able to provide an additional 2,300 patient visits to underserved and rural communities in Southern Arizona.
Nicolas I. Lopez-Galvez, MPH, a doctoral student in the environmental health sciences program at the UA Mel and Enid Zuckerman College of Public Health, is investigating a possible epidemic of kidney disease among farmworkers in Northern Mexico.
Jane Carrington, PhD, RN, FAAN, and Kimberly Shea, PhD, RN, CHPN, professors at the UA College of Nursing, have been selected to the prestigious Fulbright Specialist Roster for three-year tenures.
The McKay Laboratory at the UA Health Sciences has taken a new approach to stop progression of age-related macular degeneration (AMD), by investigating if a current FDA approved drug – carbidopa-levodopa, used to treat Parkinson’s disease – could treat or even prevent AMD.
Internationally recognized expert on genetics and genomic medicine Kenneth S. Ramos, MD, PhD, PharmB, will deliver the keynote address, “The Power of Precision Medicine,” at the UA Arthritis Center’s 17th Annual Living Healthy With Arthritis Conference, Saturday, Feb. 16.
UA researchers have discovered that metformin, a drug commonly used to treat type 2 diabetes, might also be used to treat heart failure with preserved ejection fraction (HFpEF), a condition predicted to affect more than 8 percent of people age 65 or older by 2020.
The New York Times
The University of Arizona Health Sciences
Facebook Twitter YouTube LinkedIn
Give Today